Medix Biochemica invests $5m to expand its recombinant antigen capabilities
The phased program will expand the recombinant portfolio to 60+ validated products by 2030
Advertisement
Medix Biochemica announced a Board-approved $5 million investment to expand its recombinant antigen and cell culture technology capabilities across its Espoo, Finland and St. Louis, Missouri facilities.
The phased program — targeting 60+ commercially available recombinant antigen products by 2030 — will fund facility expansion, new analytical instrumentation, and at least 10 specialized hires across both sites. Priority clinical areas include hormones, infectious disease, and tumor antigens, with subsequent phases focused on scale-up, cross-platform validation, and large-scale manufacturing.
The investment responds to growing supply chain pressure on native biological materials, which face sourcing constraints, lot-to-lot variability, and tightening regulatory requirements around animal-derived inputs. Recombinant antigens offer IVD manufacturers a more stable, consistent alternative.
"IVD manufacturers need raw material partners who can support them not just for this product cycle, but for the next decade," said Matt Lee, VP Quality Control Business Unit, of Medix Biochemica. "Our recombinant expansion is a long-term commitment to supply security, scalable production, and the performance consistency their QC pipelines depend on."
Medix Biochemica developed this recombinant program with direct input from manufacturing partners, with emphasis on technical documentation, stability data, and qualification support required when transitioning raw material sources. The shift from native to recombinant sourcing also reduces reliance on animal-derived materials, aligning with broader IVD supply chain sustainability commitments.
Recombinant evaluation packages — samples, technical data, and pipeline discussions — will be available to qualified partners beginning Q2 2026.
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Cell culture technology
Cell culture technology is a central pillar in biotechnological and pharmaceutical research and development. It enables the growth and maintenance of cells under controlled laboratory conditions, providing a window into the molecular and cellular processes of life.
Topic world Cell culture technology
Cell culture technology is a central pillar in biotechnological and pharmaceutical research and development. It enables the growth and maintenance of cells under controlled laboratory conditions, providing a window into the molecular and cellular processes of life.